Two GLP-1 receptor agonists designed to activate different signaling pathways did not differ in their effects on lipid metabolism in hyperlipidemic mice, though the G protein-biased version was better at controlling blood sugar and preventing weight gain.
No differential lipid effectDespite opposite signaling biases at the GLP-1 receptor, the two agonists produced equivalent effects on triglyceride and cholesterol levels in hyperlipidemic mice
What the researchers found
The G protein-biased agonist acyl-ExF1, when given peripherally for 6 weeks, prevented body weight gain and reduced plasma glucose levels, while the β-arrestin-biased agonist acyl-ExD3 did not. However, neither agonist significantly affected circulating lipid levels when given peripherally.
In contrast, when administered directly into the brain (intracerebroventricular infusion for 18 days), both agonists strongly reduced plasma triglyceride and cholesterol levels but did not affect glucose levels. Both increased fatty acid uptake by adipose tissue — acyl-ExD3 significantly in brown adipose tissue, acyl-ExF1 in white adipose tissue. The key finding is that signaling bias at the GLP-1 receptor does not differentially affect lipid metabolism.
Why it matters
Pharmaceutical companies are designing next-generation GLP-1 drugs that preferentially activate specific signaling pathways, hoping to separate beneficial effects from side effects. This study shows that while signaling bias matters for blood sugar and weight control, it doesn't make a difference for lipid metabolism — an important finding for drug design strategy.
How the study worked
Hyperlipidemic APOE*3-Leiden.CETP transgenic mice were treated with either saline, acyl-ExD3 (β-arrestin-biased), or acyl-ExF1 (G protein-biased) via intraperitoneal injection for 6 weeks or intracerebroventricular infusion for 18 days. Body weight, composition, and plasma levels of glucose, triglycerides, and cholesterol were monitored. At endpoint, labeled VLDL-like particles were used to track triglyceride-derived fatty acid uptake by brown and white adipose tissue.
What this study cannot tell us
This is an animal study using transgenic mice, so results may not directly translate to humans. The two signaling bias profiles were compared using modified exendin-4 compounds, not clinically approved drugs. Central administration (directly into the brain) is not a viable clinical delivery route. The study duration was relatively short, and long-term lipid effects may differ.
How to read the evidence
This is a preclinical animal study using a well-established transgenic mouse model of hyperlipidemia. The experimental design includes appropriate controls and multiple administration routes, providing mechanistic insights, but results are limited to the mouse model.
When this study was published
Published in 2025, this is a very recent study reflecting cutting-edge research in biased agonism at the GLP-1 receptor.
The bigger picture
Biased agonism — designing drugs that selectively activate one signaling pathway over another at the same receptor — is a major frontier in drug development. This study adds nuance to the field by showing that while bias matters for some GLP-1 effects (glucose, weight), it may not matter for others (lipids). It also highlights the brain as a critical mediator of GLP-1's lipid-lowering effects, which has implications for oral vs. injectable drug design.
Questions still open
- Does signaling bias at the GLP-1 receptor differentially affect lipid metabolism in humans, unlike in this mouse model?
- Why does central vs. peripheral GLP-1 receptor activation produce such different effects on lipids vs. glucose?
- Could brain-penetrating GLP-1 drugs offer superior lipid-lowering benefits compared to peripherally restricted formulations?
Common questions
What is biased agonism and why does it matter for GLP-1 drugs?
Why did the drugs work differently when given to the brain vs. the body?
Read the original research
Oppositely biased glucagon-like peptide-1 receptor agonism does not differentially affect lipid metabolism in APOE*3-Leiden CETP mice.
Diabetes, obesity & metabolism, 27(6), 3477-3489
Citation
Modder, Melanie; Tomas, Alejandra; Afkir, Salwa; Pronk, Amanda C M; Streefland, Trea C M; Lalai, Reshma A; van Eenige, Robin; Rensen, Patrick C N; Jones, Ben; Kooijman, Sander. (2025). Oppositely biased glucagon-like peptide-1 receptor agonism does not differentially affect lipid metabolism in APOE*3-Leiden CETP mice.. Diabetes, obesity & metabolism, 27(6), 3477-3489. https://doi.org/10.1111/dom.16374